Use of Checkpoint Inhibitors in a Kidney Transplant Recipient with Metastatic Cancer

Clin J Am Soc Nephrol. 2020 Aug 7;15(8):1190-1192. doi: 10.2215/CJN.15941219. Epub 2020 Mar 23.
No abstract available

Keywords: Neoplasms; Second Primary; cancer; kidney transplantation; rejection; renal transplantation.

Publication types

  • Case Reports
  • Clinical Conference

MeSH terms

  • Aged
  • Carcinoma, Squamous Cell / drug therapy*
  • Carcinoma, Squamous Cell / immunology
  • Carcinoma, Squamous Cell / secondary
  • Graft Rejection / immunology
  • Graft Rejection / prevention & control*
  • Graft Survival / drug effects
  • Humans
  • Immune Checkpoint Inhibitors / adverse effects
  • Immune Checkpoint Inhibitors / therapeutic use*
  • Immunosuppressive Agents / administration & dosage*
  • Immunosuppressive Agents / adverse effects
  • Kidney Transplantation*
  • Male
  • Nivolumab / adverse effects
  • Nivolumab / therapeutic use*
  • Polycystic Kidney, Autosomal Dominant / diagnosis
  • Polycystic Kidney, Autosomal Dominant / surgery*
  • Risk Assessment
  • Risk Factors
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / immunology
  • Skin Neoplasms / pathology
  • Treatment Outcome

Substances

  • Immune Checkpoint Inhibitors
  • Immunosuppressive Agents
  • Nivolumab